更新于：2024-05-01
Amlodipine Besylate/Benazepril Hydrochloride
氨氯地平贝那普利
更新于：2024-05-01
概要
基本信息
药物类型 小分子化药 |
别名 Amlodipine Besylate and Benazepril Hydrochloride、Amlodipine/benazepril、Lotrel + [1] |
作用机制 ACE抑制剂(血管紧张素转化酶抑制剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-03-03), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C26H31ClN2O8S |
InChIKeyZPBWCRDSRKPIDG-UHFFFAOYSA-N |
CAS号111470-99-6 |
查看全部结构式(2)
关联
37
项与 氨氯地平贝那普利 相关的临床试验氨氯地平贝那普利胶囊在健康人群中的生物等效性试验
健康成年受试者在空腹状态下单次口服氨氯地平贝那普利胶囊的随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉设计的生物等效性试验
评估受试制剂氨氯地平贝那普利胶囊（规格：5 mg:10 mg）与参比制剂Lotrel®（规格：5 mg:10 mg）在健康成年受试者空腹和餐后状态下的单中心、开放、随机、单剂量、交叉生物等效性研究
100 项与 氨氯地平贝那普利 相关的临床结果
登录后查看更多信息
100 项与 氨氯地平贝那普利 相关的转化医学
登录后查看更多信息
100 项与 氨氯地平贝那普利 相关的专利（医药）
登录后查看更多信息
9
项与 氨氯地平贝那普利 相关的文献（医药）2013-07-01American Journal of Hypertension3区 · 医学
Dynamic View on Affordability of Fixed-Dose Combination Antihypertensive Drug Therapy
3区 · 医学
Article
作者: Hong, Song Hee ; Wang, Junling ; Tang, Jun
BACKGROUND:
The use of fixed-dose combinations (FDCs) has been increasing since the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommended using ≥2 drugs as the first-line drug therapy for patients with stage 2 hypertension. FDCs simplify the drug therapy regimen and reportedly lower the drug therapy cost compared with the free combination (FC) of 2 single-agent drugs. This study hypothesized that the affordability of FDCs over FCs would change over time depending on the availability of generic single-agent drugs.
METHODS:
This study used the 2009 Medical Expenditure Panel Survey. Antihypertensive drugs were identified based on the Food and Drug Administration national drug directory. Based on the 2 databases, regression models were run to predict average monthly drug cost as well as out-of-pocket cost for each prescription along with their 95% confidence intervals (CIs).
RESULTS:
Overall, FDCs (n = 26) had average monthly drug costs similar to respective FCs when FCs were not generically available. However, when FCs were generically available, FDCs (n = 11) had average drugs costs much higher than their respective FCs. For example, Lotrel as an FDC had an average monthly drug cost of $115.97 (95% CI = $96.59-$135.36), whereas its counterpart FC had an average monthly drug cost of $21.00 (95% CI = $18.23-$23.79).
CONCLUSIONS:
The cost advantage of FDCs over FCs was reversed when FCs were generically available. The finding of this study informs patients, health-care providers, and drug plans of the importance of making dynamic decisions on preferred drug therapy options depending on the availability of generic drugs.
2011-06-01Expert Review of Cardiovascular Therapy
Renoprotective effects of benazepril: current perspective
Review
作者: Stompoor, Tomasz ; Napora, Maria ; Olszewski, Artur
Cardiovascular (CV) disease, its associated risk factors and continued progression run in parallel with renal deterioration (cardio-renal syndrome). Most guidelines promote early treatment, including the use of ACE inhibitors to control CV risk in patients with chronic renal failure. The renoprotective effects of the ACE inhibitor, benazepril, independent of blood pressure control, have been demonstrated, as monotherapy or in combination with amlodipine or hydrochlorothiazide, in large clinical trials: Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) and Gauging Albuminuria Reduction with Lotrel in Diabetic Patients with Hypertension (GUARD) in patients with mild-to-severe chronic kidney disease. In the ACCOMPLISH trial, CV outcomes and renoprotective effects were greater in patients receiving benazepril in combination with amlodipine; the GUARD trial demonstrated that combined benazepril/hydrochlorothiazide was more effective than amlodipine combined with benazepril in reducing baseline urinary albumin:creatinine ratio and normalizing urinary albumin:creatinine ratio in patients with baseline microalbuminuria, although this effect was accompanied with a greater decrease in glomerular filtration rate than with benazepril/amlodipine. While this is not a study in patients with overt renal disease (patients had severe CV diseases), the ACCOMPLISH trial is the first large study to date to show the added benefit of combining ACE inhibitors and calcium-channel blockers in renal protection. Future large, well-controlled trials, designed to evaluate hard renal outcomes, are required to identify which patients will benefit most from particular combination treatment strategies in renoprotection.
2009-10-01Hypertension1区 · 医学
Magnetic Resonance Imaging Left Ventricular Mass Reduction With Fixed-Dose Angiotensin-Converting Enzyme Inhibitor-Based Regimens in Patients With High-Risk Hypertension
1区 · 医学
Article
作者: Reichek, Nathaniel ; Devereux, Richard B. ; Rocha, Ricardo A. ; Hilkert, Robert ; Hall, Donna ; Purkayastha, Das ; Pitt, Bertram
Left ventricular hypertrophy, a major cardiovascular risk factor for morbidity and mortality, is commonly caused by arterial hypertension. The renin-angiotensin-aldosterone system may contribute to the pathogenesis of left ventricular hypertrophy. The Assessment of Lotrel in Left Ventricular Hypertrophy and Hypertension Study compared a single-pill combination of amlodipine/benazepril at doses 5.0/20.0 mg, 5.0/40.0 mg, and 10.0/40.0 mg with hydrochlorothiazide/benazepril at doses 12.5/20.0 mg, 12.5/40.0 mg, and 25.0/40.0 mg on the reduction of left ventricular mass index measured by cardiac MRI in stage 2 hypertensive patients over 52 weeks of treatment in a randomized clinical trial. A total of 125 male and female patients, > or =55 years of age, with echocardiographic left ventricular hypertrophy and high-risk hypertension defined as blood pressure > or =160/100 mm Hg or current antihypertensive treatment were enrolled. After 52 weeks of treatment, left ventricular mass index was significantly reduced from baseline with amlodipine/benazepril (mean: 10.16 g/m(2)) or hydrochlorothiazide/benazepril (mean: 6.74 g/m(2); both P<0.0001), with a mean difference between treatment groups of 3.36 g/m(2) (P=0.16). No significant treatment differences were observed in subgroups defined by age, male gender, race, diabetes status, or dose level. However, in female patients, left ventricular mass index reduction was greater with amlodipine/benazepril (P=0.02). Both treatments were well tolerated.
100 项与 氨氯地平贝那普利 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 高血压 | 批准上市 | 中国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 11,506 | (Benazepril/Amlodipine) | 鏇獵齋窪築衊鬱築繭壓(齋顧窪蓋淵鏇繭夢蓋簾) = 顧齋積選窪鏇鬱鹽鹹網 憲鑰蓋觸壓鑰獵構糧願 (憲醖蓋顧範願繭網構顧, 繭範範構獵壓夢鑰醖淵 ~ 蓋夢築觸積蓋製鏇窪構) 更多 | - | 2011-05-17 | ||
(Benazepril/Hydrochlorothiazide) | 鏇獵齋窪築衊鬱築繭壓(齋顧窪蓋淵鏇繭夢蓋簾) = 範衊醖願願觸觸築鑰淵 憲鑰蓋觸壓鑰獵構糧願 (憲醖蓋顧範願繭網構顧, 鬱鏇糧積構夢築繭鏇夢 ~ 鹽獵鹹鑰鹹積鹹構鹽積) 更多 | ||||||
临床4期 | 226 | 夢餘範鬱繭餘觸艱齋醖(憲廠築憲繭簾鹽繭襯簾) = more frequently reported in the amlodipine/benazepril group than in the valsartan/hydrochlorothiazide group 壓淵鹹憲願壓簾餘襯製 (廠壓淵鑰鹹製鏇製鬱繭 ) | - | 2012-08-01 | |||
临床1期 | - | 68 | (Amlodipine Benazepril) | (範鑰積範繭獵艱積鬱顧) = 鏇蓋鹹築壓鏇襯衊齋窪 蓋網構膚憲餘鹹積鏇憲 (網顧簾衊壓窪壓鹽製範, 廠廠鹽鹽壓願膚顧製鑰 ~ 艱膚範獵壓鹽顧鹹壓醖) 更多 | - | 2009-08-18 | |
(Lotrel®) | (範鑰積範繭獵艱積鬱顧) = 獵鏇獵範窪網獵鏇鑰鹽 蓋網構膚憲餘鹹積鏇憲 (網顧簾衊壓窪壓鹽製範, 壓遞餘築淵願積遞鬱鹽 ~ 觸獵顧觸鹹壓鑰餘選顧) 更多 | ||||||
N/A | 259 | (憲鹽繭蓋餘遞糧艱範艱) = 蓋齋鬱積蓋選艱艱遞繭 顧願糧壓獵齋鑰築範網 (範簾鬱膚糧壓簾鬱廠醖 ) 更多 | 积极 | 2010-06-01 | |||
Amlodipine monotherapy | (憲鹽繭蓋餘遞糧艱範艱) = 廠夢積壓觸醖糧構獵繭 顧願糧壓獵齋鑰築範網 (範簾鬱膚糧壓簾鬱廠醖 ) 更多 | ||||||
临床1期 | - | 48 | (Amlodipine Benazepril) | (壓觸選築繭獵艱壓鑰簾) = 鏇齋顧觸簾選艱簾簾鑰 鹹鹹願鹽淵顧餘願觸網 (觸繭範淵鹽築獵願網夢, 糧夢築遞廠簾選積遞壓 ~ 齋築觸憲鬱獵簾獵築鏇) 更多 | - | 2009-08-18 | |
(Lotrel®) | (壓觸選築繭獵艱壓鑰簾) = 窪網顧廠鏇齋廠夢鏇窪 鹹鹹願鹽淵顧餘願觸網 (觸繭範淵鹽築獵願網夢, 遞顧餘艱膚範觸廠積壓 ~ 製鹹淵繭繭鏇簾淵淵糧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用